---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000859"
form_type: "8-K"
ticker: "BBNX"
cik: "0001674632"
company_name: "Beta Bionics, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:27:06.182720+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Beta Bionics Q4 2025 revenue $32.1M (+57% YoY); guides FY2026 $130-135M

## Summary
- Net sales $32.1M in Q4 (+57% YoY); full year $100.3M (+54%). Installed base 35,011 users (+129%).
- Gross margin 59% Q4 (up 179bps); FY gross margin 55.4%. Net loss $13.5M Q4 (improved from $18.1M).
- 2026 guidance: revenue $130M-$135M; PBP channel 36-38% of new starts; gross margin 55.5%-57.5%.
- Bihormonal system Phase 2a first-in-human trial completed in New Zealand; additional Phase 2a expected H1 2026.
- Cash $264.7M as of Dec 31, 2025. New patient starts up 37% Q4 to 5,592.

## SEC filing metadata
- accession: 0001171843-26-000859
- form_type: 8-K
- ticker: BBNX
- cik: 0001674632
- company_name: Beta Bionics, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674632/000117184326000859/0001171843-26-000859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674632/000117184326000859/f8k_021326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000859
- JSON: https://secwatch.observer/filing/0001171843-26-000859.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.